文献速递系统性红斑狼疮

含V-set免疫球蛋白结构域蛋白4作为狼疮肾炎及肾脏病理活动性的新型血清生物标志物

V-Set Immunoglobulin Domain-Containing Protein 4 as a Novel Serum Biomarker of Lupus Nephritis and Renal Pathology Activity.
PubMed 文献 · Arthritis Rheumatol · 2023-07-04

研究通过定量蛋白微阵列筛选狼疮肾炎患者血清高丰度蛋白,在81份和155份血清样本中验证候选标志物,发现VSIG4区分狼疮肾炎与健康对照的曲线下面积为0.93,可区分活动性与非活动性狼疮肾炎,且与SLEDAI评分、尿蛋白肌酐比、血肌酐及肾脏病理活动性指数相关。

要点

  • VSIG4区分狼疮肾炎与健康对照的曲线下面积为0.93。
  • 血清VSIG4水平与SLEDAI评分、肾脏SLEDAI域评分、尿蛋白肌酐比及血肌酐正相关。
  • 血清VSIG4水平纵向追踪狼疮肾炎疾病活动性,并反映肾脏病理活动性指数。

核心结论

  • VSIG4可能是狼疮肾炎患者有前景的新型血清生物标志物和治疗靶点。

研究设计与样本

  • 使用定量蛋白微阵列筛选狼疮肾炎患者血清高丰度蛋白,并与健康对照比较。
  • 用81份狼疮肾炎患者和对照者血清样本通过酶联免疫吸附测定验证候选蛋白。
  • 用155份狼疮肾炎患者和对照者血清样本进一步验证机器学习模型筛选的标志物。

主要发现

  • 筛选阶段共发现13种蛋白在狼疮肾炎患者血清中显著升高,其中8种蛋白通过酶联免疫吸附测定在81份血清样本中验证。
  • 通过特征重要性分析识别出3种具有狼疮肾炎诊断潜力的血清标志物,并在155份血清样本中进一步验证。
  • VSIG4区分狼疮肾炎与健康对照的曲线下面积为0.93,且可区分活动性与非活动性狼疮肾炎。
  • 血清VSIG4水平与SLEDAI评分正相关(Spearman秩相关系数rs=0.42,P<0.001),与SLEDAI肾脏域评分正相关(rs=0.46,P<0.001)。
  • 血清VSIG4水平与尿蛋白肌酐比正相关(rs=0.56,P<0.001),与血肌酐水平正相关(rs=0.41,P<0.001)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To discover novel serum biomarkers that have diagnostic or predictive value in lupus nephritis (LN). METHODS: Using a quantitative protein microarray, we screened for high-abundant proteome expression in the serum of patients with LN compared to healthy controls. Top candidates from this screening were validated using a larger cohort of patients with LN compared to a disease control cohort (subjects with other chronic kidney diseases) and a healthy control cohort. Promising markers were then selected using a machine-learning model and further validated with a larger patient cohort. The corresponding autoantibodies and immune complexes containing these proteins were also examined. RESULTS: In total, 13 proteins were found to be significantly elevated in LN patient serum in the screening, among which 8 proteins were validated by enzyme-linked immunosorbent assay using 81 serum samples from LN patients and control subjects. Three serum markers with LN diagnostic potential were identified using feature importance analysis and further validated using 155 serum samples from LN patients and control subjects. V-set immunoglobulin domain-containing protein 4 (VSIG4) appeared to be the most promising marker in distinguishing LN from healthy controls, with an area under the curve of 0.93. VSIG4 could also discriminate active LN from inactive LN. Furthermore, serum VSIG4 levels were positively correlated with all of the following clinical parameters: the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score (Spearman's rank correlation rs = 0.42, P < 0.001), the renal domain score of the SLEDAI (rs = 0.46, P < 0.001), the urinary protein-to-creatinine ratio (rs = 0.56, P < 0.001), and the serum creatinine level (rs = 0.41, P < 0.001). Importantly, we found that serum VSIG4 levels tracked with LN disease activity longitudinally, and that serum VSIG4 levels reflected the renal pathology activity index (AI), particularly the AI components of crescent formation and hyaline deposits. CONCLUSION: VSIG4 may be a promising novel serum biomarker and therapeutic target in patients with LN.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Tang C, Zhang S, Teymur A, et al. V-Set Immunoglobulin Domain-Containing Protein 4 as a Novel Serum Biomarker of Lupus Nephritis and Renal Pathology Activity. Arthritis Rheumatol. 2023. PMID: 37163449. doi:10.1002/art.42545

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。